help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pravinkumar, E.
Right arrow Articles by Sherwood, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pravinkumar, E.
Right arrow Articles by Sherwood, E. R.
American Journal of Respiratory and Critical Care Medicine Vol 169. pp. 655-656, (2004)
© 2004 American Thoracic Society


Correspondence

Balance of Inflammation in Sepsis

To the Editor:

In their study, Sherwood and colleagues (1) look at mainly the proinflammatory cytokines in addition to CD8+ T cells and natural killer cell activity. Despite its expense, modulation of proinflammatory response alone in sepsis has not shown any benefit on mortality rate in septic patients (2). Compensatory antiinflammatory response leads to monocyte/macrophage hyporesponsiveness, resulting in the suppression of proinflammatory cytokines. Inflammatory cytokines, such as IFN-{gamma}, interleukin (IL)-12, and granulocyte colony-simulating factor, have been tried in the past to overcome this (3). Therefore, there remains a balance between the proinflammatory and antiinflammatory cytokines in regulating the outcome in sepsis. This balance seems crucial because failure to achieve this balance can lead to multiorgan failure and poor outcome in sepsis, either because of the uncontrolled inflammation or the profound antiinflammation and downregulation of antigen-presenting cells (4).

Although Sherwood and colleagues (1) looked at the CD8+ T cells and natural killer cells along with Th1 cytokines, it certainly would have been interesting to know the levels of IL-10, a potent immunomodulatory cytokine, and IL-4, the index cytokine of Th2 cell activity. IL-10 not only limits and halts the inflammatory response, but it also regulates the proliferation of T cells, B cells, natural killer cells, antigen-presenting cells, mast cells, and granulocytes (5).

Heidecke and colleagues (6) showed that unbalanced production of proinflammatory and antiinflammatory cytokines occur in patients with severe intraabdominal infection, with severe suppression of tumor necrosis factor-{alpha} in nonsurvivors. Hence, there must be cautious optimism in postulating therapies in sepsis, directed either at proinflammatory or antiinflammatory cytokines alone.

Egbert Pravinkumar

Institute of Medical Sciences Aberdeen, Scotland, United Kingdom

FOOTNOTES

Conflict of Interest Statement: E.P. has no declared conflict of interest.

REFERENCES

  1. Sherwood ER, Lin CY, Tao W, Hartmann CA, Dujon JE, French AJ, Varma TK. ß2 Microglobulin knockout mice are resistant to lethal intraabdominal sepsis. Am J Respir Crit Care Med 2003;167:1641–1649.[Abstract/Free Full Text]
  2. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998;26:1927–1931.[CrossRef][Medline]
  3. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Peinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN{gamma} treatment. Nat Med 1997;3:678–681.[CrossRef][Medline]
  4. Bone RC. Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 1996;24:1125–1128.[CrossRef][Medline]
  5. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy: review of a new approach. Pharmacol Rev 2003;55:241–269.[Abstract/Free Full Text]
  6. Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, Siewert JR, Holzmann B. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 1999;178:288–292.[CrossRef][Medline]

 

From the Authors:

I read Dr. Pravinkumar's letter with great interest and appreciate his comments. Our recent article (1) examined the response of ß2 microglobulin knockout mice to acute intraabdominal sepsis. We found that ß2 microglobulin knockout mice treated with anti-asialoGM1 exhibit greater than 70% long-term survival after cecal ligation and puncture. The improved survival was associated with decreased production of proinflammatory cytokines, less hypothermia, and improved acid–base balance. The novel finding of our work is that CD8+ T and natural killer cells contribute to the proinflammatory response associated with acute peritonitis. Most prior investigations have focused on macrophage function during the early proinflammatory phase of sepsis (2).

The model of sepsis used in our studies is rapidly lethal and causes mortality of wild-type mice within 24 to 30 hours. This mimics the clinical presentation of patients with severe acute peritonitis. Clinically, most patients with acute peritonitis can be effectively treated during this early inflammatory phase with fluid resuscitation, surgery, and antibiotics. However, our findings provide a better understanding of the underlying mechanisms mediating the systemic inflammatory response during acute peritonitis.

There are many underlying causes of sepsis, all of which have differences in pathophysiology. Furthermore, individual patients are likely to pass through different phases of sepsis ranging from an early proinflammatory phase (systemic inflammatory response syndrome) to later immunoparalysis (compensatory antiinflammatory response) (3). Some have speculated that these phases may coexist. The factors that have been classically used to define sepsis are physiologic (4), yet much of the pathogenesis of sepsis is caused by immunologic alterations. Many investigators are working to identify markers that will define the immunologic status of the septic patient (5, 6). On the basis of immunologic conditions, targeted immunotherapy could be provided. For example, antiinflammatory therapies may be beneficial in patients exhibiting a proinflammatory phenotype, whereas they may worsen immunosuppression and increase the risk for mortality in patients with immunoparalysis.

Therefore, I fully agree with Dr. Pravinkumar. The pathogenesis of sepsis is dependent on a complex interplay of proinflammatory and antiinflammatory mediators that change over time. Our study addresses factors that are important during the early proinflammatory phase of septic peritonitis. Hopefully, treatment of clinical sepsis will improve as our understanding of this complex disease process advances.

Edward R. Sherwood

The University of Texas Medical Branch Galveston, Texas

FOOTNOTES

Conflict of Interest Statement: E.R.S. has no declared conflict of interest.

REFERENCES

  1. Sherwood ER, Lin CY, Tao W, Hartmann CA, Dujon JE, French AJ, Varma TK. ß2 Microglobulin knockout mice are resistant to lethal intraabdominal sepsis. Am J Respir Crit Care Med 2003;167:1641–1649.
  2. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996;4:407–414.[CrossRef][Medline]
  3. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001;16:83–96.[Medline]
  4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.
  5. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17:463–467.[CrossRef][Medline]
  6. Hynninen M, Pettila VV, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M. Predictive value of monocyte histocompatibility leukocyte antigen-dr expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 2003;20:1–4.[Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pravinkumar, E.
Right arrow Articles by Sherwood, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pravinkumar, E.
Right arrow Articles by Sherwood, E. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2004 American Thoracic Society